04:48 PM EDT, 03/22/2024 (MT Newswires) -- Denali Therapeutics ( DNLI ) filed a registration statement Friday for the potential resale of up to 29.3 million shares from time to time by selling shareholders.

The statement covers nearly 3.24 million outstanding shares and 26 million issuable on the exercise of pre-funded warrants from selling shareholders from a private placement in February, according to the filing.

The company said it will not receive any of the proceeds from the sale of shares being offered by selling shareholders but will get the exercise price of any pre-funded warrants by cash payment.

Shares of the company fell 5.5% in after-hours trading. They dropped 6.6% in the regular session.

Price: 18.55, Change: -1.07, Percent Change: -5.45